MAP6

Across TCGA pan-cancer cohorts, MAP6 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MAP6 data layer compared with 20 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher MAP6 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated MAP6 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LSCC show a favorable association.

PDAC, LUAD, and LSCC are the cancer types where MAP6 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	IV	0.785	0.214	.006	16	view →
LUAD	DFS	Quartile	II,III,IV	0.291	0.758	.013	10	view →
LSCC	DFS	Median	III,IV	0.925	0.650	.020	8	view →
HNSC	OS	Median	All	0.259	0.825	.027	4	view →
GBM	DFS	Tertile	All	0.841	0.603	.015	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

MAP6–PDAC (DFS)

Open the PDAC breakdown →